Top

Irish Journal of Medical Science (1971 -)

Published in:

01-08-2020 | NSCLC | Original Article

Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib

Authors: Ye Qiu, Xinyun He, Zepei Li, Yulan Jiang, Yuming Jia

Published in: Irish Journal of Medical Science (1971 -) | Issue 3/2020

Abstract

Background

Lung cancer is a disease that severely endangers human health. Non-small cell lung cancer (NSCLC) accounts for approximately 4/5 of lung cancers.

Aims

To investigate the efficacy of early combination of local radiotherapy and granulocyte macrophage colony-stimulating factor (GM-CSF) for advanced NSCLC treated with icotinib.

Methods

Forty-two patients with stage IV NSCLC complicated with EGFR gene mutation were selected and randomly divided into two groups, with 21 patients in each group. Patients in control group were treated with icotinib, and patients in experimental group were treated with icotinib combined with local radiotherapy and subcutaneous injection of GM-CSF. One-year progression free survival between two groups was compared.

Results

Three months after treatment, the efficacy in experimental group was significantly better than that in control group, and objective response rate was 95.24% in experimental group, which was higher than the 71.43% in control group. Patients in experimental group had no differences in white blood cell and neutrophil, but had significantly lower carcino-embryonic antigen and neuron-specific enolase levels and higher CD3+, CD4+, and CD4+/CD8+ than those in control group and before treatment. There were no differences in the proportion of patients with adverse reactions between two groups. One-year progression free survival was significantly better in experimental group than in control group.

Conclusions

Early combination of local radiotherapy and GM-CSF has a significant efficacy for advanced NSCLC accounts for approximately 4/5 of lung cancers treated with icotinib, and it can improve patients’ autoimmunity and lengthen progression free survival.

Leal TA, Ramalingam SS (2018) Immunotherapy in previously treated non-small cell lung cancer (NSCLC). J Thorac Dis 10:S422–Ss32. https://doi.org/10.21037/jtd.2018.01.141 CrossRefPubMedPubMedCentral

Rotow J, Bivona TG (2017) Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 17:637–658. https://doi.org/10.1038/nrc.2017.84 CrossRefPubMed

Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghi M et al (2017) Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going. Crit Rev Oncol Hematol 117:38–47. https://doi.org/10.1016/j.critrevonc.2017.07.003 CrossRefPubMed

Lee DH (2017) Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures. Pharmacol Ther 174:1–21. https://doi.org/10.1016/j.pharmthera.2017.02.001 CrossRefPubMed

Ghafoor Q, Baijal S, Taniere P, O'Sullivan B, Evans M, Middleton G (2018) Epidermal growth factor receptor (EGFR) kinase inhibitors and non-small cell lung cancer (NSCLC)-advances in molecular diagnostic techniques to facilitate targeted therapy. Pathol Oncol Res 24:723–731. https://doi.org/10.1007/s12253-017-0377-1 CrossRefPubMed

Bruckl W, Tufman A, Huber RM (2017) Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Expert Rev Anticancer Ther 17:143–155. https://doi.org/10.1080/14737140.2017.1266265 CrossRefPubMed

Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP et al (2017) Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol 28:2715–2724CrossRef

Zou B, Lee VHF, Yan H (2018) Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis. BMC Bioinforma 19:88. https://doi.org/10.1186/s12859-018-2093-6 CrossRef

Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T et al (2017) Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO open 2:e000214CrossRef

10.

Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, Demaria S, Formenti S (2015) Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 25:54–64. https://doi.org/10.1016/j.semradonc.2014.07.003 CrossRefPubMedPubMedCentral

11.

Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish I, Newbold KL, Goldsweig H, Coffin R, Nutting CM (2010) Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 16:4005–4015CrossRef

12.

Liang XT, Wu J (2016) Application of ECOG rating scale in graded nursing of patients with lung cancer chemotherapy. J Prey Med Chin PLA 34:125–126

13.

Guenther LM, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, et al (2018) Response evaluation criteria in solid tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer 65. https://doi.org/10.1002/pbc.26896

14.

Ma HL, Zhang HT (2014) Effect of chemotherapy combined with traditional Chinese medicine on immune function and KPS score in patients with advanced non-small cell lung cancer. Hainan Med J 2014:2271–2272

15.

Chen DF, Sun WJ, Xiong J (2012) The diagnosis and treatment of drug-induced liver injury. Chin J Hepatol 20:170–172. https://doi.org/10.1016/j.fertnstert.2004.02.108 CrossRef

16.

Dai Y (2012) Clinical observation of Yifei Jiedu decoction combined with PP regimen in the treatment of advanced non-small cell lung cancer: Nanjing University of traditional Chinese medicine 2012

17.

Lakshmi SP, Reddy AT, Banno A, Reddy RC (2017) PPAR agonists for the prevention and treatment of lung cancer. PPAR Res 2017:8252796. https://doi.org/10.1155/2017/8252796 CrossRefPubMedPubMedCentral

18.

Sharma AVB, Park YS (2018) Role of probiotics in the management of lung cancer and related diseases: an update. J Funct Foods 40:625–633. https://doi.org/10.1016/j.jff.2017.11.050 CrossRef

19.

Chang CH, Lee CH, Ko JC, Chang LY, Lee MC, Wang JY, Yu CJ (2017) Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan. Cancer Med 6:1563–1572. https://doi.org/10.1002/cam4.1121 CrossRefPubMedPubMedCentral

20.

Zhou J, Song XB, He H, Zhou Y, Lu XJ, Ying BW (2016) Prevalence and clinical profile of EGFR mutation in non-small-cell lung carcinoma patients in Southwest China. Asian Pac J Cancer Prev 17:965–971. https://doi.org/10.7314/APJCP.2016.17.3.965 CrossRefPubMed

21.

Yang Z, Tam KY (2018) Combination strategies using EGFR-TKi in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes. Int J Biol Sci 14:204–216. https://doi.org/10.7150/ijbs.22955 CrossRefPubMedPubMedCentral

22.

Liu HL (2016) Clinical observation of pemetrexed monotherapy or combined with gefitinib in the treatment of advanced lung adenocarcinoma after EGFR-TKI resistance: Zhengzhou University 2016

23.

Xia GH, Zeng Y, Fang Y, Yu SR, Wang L, Shi MQ et al (2014) Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI. Cancer Biol Med 11:270–276PubMedPubMedCentral

24.

Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK (2017) A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine (Taipei) 7:23. https://doi.org/10.1051/bmdcn/2017070423 CrossRef

25.

Nebiker CA, Han J, Eppenberger-Castori S, Iezzi G, Hirt C, Amicarella F, Cremonesi E, Huber X, Padovan E, Angrisani B, Droeser RA, Rosso R, Bolli M, Oertli D, von Holzen U, Adamina M, Muraro MG, Mengus C, Zajac P, Sconocchia G, Zuber M, Tornillo L, Terracciano L, Spagnoli GC (2014) GM-CSF production by tumor cells is associated with improved survival in colorectal cancer. Clin Cancer Res 20:3094–3106. https://doi.org/10.1158/1078-0432.CCR-13-2774 CrossRefPubMed

26.

Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC (2015) Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 16:795–803. https://doi.org/10.1016/S1470-2045(15)00054-6 CrossRefPubMed

27.

Chang CC, Chi KH, Kao SJ, Hsu PS, Tsang YW, Chang HJ, Yeh YW, Hsieh YS, Jiang JS (2011) Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer 73:189–194. https://doi.org/10.1016/j.lungcan.2010.12.007 CrossRefPubMed

28.

Deng G, Hu P, Zhang J, Liu Q, Liang N, Xie J et al (2016) Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer. Oncotarget 7:85142–85150. https://doi.org/10.18632/oncotarget.13202 CrossRefPubMedPubMedCentral

29.

Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN (2014) Clinical use of dendritic cells for cancer therapy. Lancet Oncol 15:e257–e267. https://doi.org/10.1016/S1470-2045(13)70585-0 CrossRefPubMed

Title: Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib
Authors: Ye Qiu
Xinyun He
Zepei Li
Yulan Jiang
Yuming Jia
Publication date: 01-08-2020
Publisher: Springer London
Keywords: NSCLC
Lung Cancer
Lung Cancer
Cancer Biomarker
NSCLC
Radiotherapy
Lung Cancer
Published in: Irish Journal of Medical Science (1971 -) / Issue 3/2020
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-019-02137-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Effects of intravenous and mask induction on post-operative emergence delirium in pediatric patients undergoing tonsillectomy with or without adenoidectomy

Psychological morbidity among forcibly displaced children—a literature review

Is Movember synonymous with moustaches or men's health? An examination of internet search activity for prostate and testicular cancer during the campaign

Unknown breastfeeding rates among Traveller women in Ireland: a systems failure to collect, record and report

High level of circulating microRNA-142 is associated with acute myocardial infarction and reduced survival

The DATA protocol: developing an educational tool to optimise note-writing in hospitals

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials